Congratulations To

LEADS BIOLABS (Stock Code: 9887.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market. 

(Source：http://www.hkex.com.hk）

CR SWCS Team is honoured to serve as LEADS BIOLABS’s Joint Company Secretary,

committed to ensuring governance, compliance, and sustained growth.